Compare · OLK vs TXG
OLK vs TXG
Side-by-side comparison of Olink Holding AB (OLK) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OLK and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- TXG carries a market cap of $8.77B.
- TXG has hit the wire 16 times in the past 4 weeks while OLK has been quiet.
- TXG has more recent analyst coverage (25 ratings vs 3 for OLK).
- Company
- Olink Holding AB
- 10x Genomics Inc.
- Price
- $26.01+0.04%
- $67.26+2.59%
- Market cap
- -
- $8.77B
- 1M return
- -
- +14.66%
- 1Y return
- -
- +434.66%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 0
- 16
- Recent ratings
- 3
- 25
Olink Holding AB
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest OLK
- SEC Form 15F-12B filed by Olink Holding AB
- SEC Form 6-K filed by Olink Holding AB
- Amendment: SEC Form SC 14D9/A filed by Olink Holding AB
- Amendment: SEC Form SC TO-T/A filed by Olink Holding AB
- SEC Form 6-K filed by Olink Holding AB
- Notice to attend the Extra General Meeting of Olink Holding AB (publ)
- SEC Form 6-K filed by Olink Holding AB
- SEC Form S-8 POS filed by Olink Holding AB
- SEC Form S-8 POS filed by Olink Holding AB
- SEC Form S-8 POS filed by Olink Holding AB
Latest TXG
- Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research
- UBS resumed coverage on 10x Genomics with a new price target
- Director Stuelpnagel John R sold $1,235,072 worth of shares (20,000 units at $61.75), decreasing direct ownership by 6% to 328,436 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by 10x Genomics Inc.
- Chief Executive Officer Saxonov Serge gifted 100 shares, decreasing direct ownership by 0.01% to 1,075,249 units (SEC Form 4)
- SEC Form 144 filed by 10x Genomics Inc.
- RBC Capital Mkts initiated coverage on 10x Genomics with a new price target
- Chief Executive Officer Saxonov Serge sold $667,901 worth of shares (10,486 units at $63.69) as part of a pre-agreed trading plan, decreasing direct ownership by 0.97% to 1,075,349 units (SEC Form 4)
- 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
- Chief Executive Officer Saxonov Serge sold $1,168,775 worth of shares (18,545 units at $63.02), decreasing direct ownership by 2% to 1,085,835 units (SEC Form 4) to satisfy tax liability